The Epinephrine Autoinjector Market is estimated to be valued at US$ 3.91 Billion by 2030

A newly published report by Coherent Market Insights reveals a sustainable growth opportunity in the epinephrine autoinjector market. Coherent Market Insights’ analyst projected the epinephrine autoinjector market to be valued at US$ 3.05 Bn in 2023. It is expected to exhibit a CAGR of 8.6 % over the forecast period 2023 -2030.

Increase in the prevalence of anaphylaxis globally drives market growth. According to a report by the American College of Allergy, Asthma and Immunology, anaphylaxis affects approximately 5% of the population in the United States each year.

Further, according to the European Academy of Allergy and Clinical Immunology, approximately 150-200 people die every year due to anaphylaxis in the UK. The growing prevalence of anaphylaxis is expected to propel the demand for epinephrine autoinjectors over the forecast period. Additionally, growing initiatives by various government and non-government organizations for raising awareness about anaphylaxis treatment is also expected to support market growth.

Key market trends include Adoption of digital health technologies: There has been increasing adoption of digital health technologies such as mobile apps and connected devices for epinephrine autoinjectors. For instance, companies are offering digital solutions such as connected epinephrine autoinjectors integrated with mobile apps, Bluetooth sensors, and digital training programs. These digital solutions can track prescription refills, provide dosage reminders, and send alerts in case of emergencies. This is expected to enhance patient engagement and safety.

Launch of generic versions: Major players in the market are focusing on launching affordable generic versions of epinephrine autoinjectors to increase their market share and make treatment affordable for patients. For instance, in December 2021, Pfizer launched its authorized generic version of the epinephrine auto-injector called Adrenaclick authorized generic. Similarly, in July 2021, Teva Pharmaceuticals USA launched its generic version of EpiPen Jr. 0.15 mg. 

Epinephrine Autoinjector Market Opportunities The growing prevalence of allergic reactions and anaphylaxis cases globally presents a major market opportunity for epinephrine autoinjector manufacturers. According to research, over 50 million Americans suffer from various food allergies with rates rising each year. Anaphylaxis caused by food, insect stings or medications can become life-threatening if not treated immediately. The need for fast-acting treatment of allergic emergencies on-the-go is driving increased adoption of easy-to-use autoinjector devices.

Loss of exclusivity and patent cliff of branded epinephrine autoinjectors is another key growth driver in this market. Market entry of generic copies of Mylan’s EpiPen, the largest selling brand, in 2018 has led to more affordable treatment options. The lower cost generic autoinjectors have boosted replacement rates and expanded the addressable patient pool. Additional generic approvals are anticipated over the forecast period, intensifying price competition and proliferating usage volumes across different dose strengths.

Key Market Takeaways:  The global epinephrine autoinjector market is anticipated to witness a CAGR of 8.6% during the forecast period 2023-2030. This is owing to the increasing prevalence of severe allergic reactions as well as patent expiries spurring genericization.

On the basis of type, the 0.3mg segment is expected to hold a dominant position, accounting for over 50% market share. This is due to its popularity for adult usage.

On the basis of end user, individual customers are expected to hold the dominant position over the forecast period. This is driven by wider patient affordability and self-purchase trends for personal or family emergency use.

On the basis of distribution channel, retail pharmacies are expected to remain the major channel distributing autoinjectors, supported by their wide network and familiarity for patients.

North America is expected to hold a dominant position over the forecast period. This is owing to high disease prevalence rates, strong branded drug sales and high patient affordability in major markets like the US.

Competitor Insights: Key players operating in the epinephrine autoinjector market include Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, and Kaleo.

Recent Developments: On September 20, 2023, the FDA denied to approve a nasal spray as an alternative to epinephrine autoinjectors like EpiPens, citing the need for further research. ARS Pharma, the drug’s manufacturer, announced that the US FDA had requested that a study be conducted. More information in full report